ERNA Ernexa Therapeutics Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ERNA — —
Key stats
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.34
Cost of Equity (CAPM)11.67%
WACC11.82%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-383.5%
Book / Price258.4% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$3.49 (Market Anchor value)
SMA 20 / Bollinger Mid$2.38
Bollinger Width / SMA202718.9% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$6.49
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $17.58 21% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.9× · 3 peers
Market Anchor (SMA50) $3.49 79% stability 72% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
5
List Date
2021-03-26
CIK
0000748592
Next Earnings
2026-11-06
EPS Forecast
($3.84) (1 est.)
Headquarters
Cambridge, MA
Homepage
https://www.ernexatx.com

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflam…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan--54.84%-11.17%2.55%5.17%12.85%
Feb---15.41%-8.77%-15.96%-77.01%-29.29%
Mar---9.81%29.03%-36.20%-29.00%-11.50%
Apr---17.12%-23.04%11.95%-29.88%-14.52%
May---31.48%6.74%11.05%177.25%40.89%
Jun--4.15%-3.68%-43.99%-27.08%-17.65%
Jul--14.00%-3.98%-4.95%-50.82%-11.44%
Aug---9.29%7.68%-14.74%32.46%4.03%
Sep---4.39%-39.31%-18.28%-26.44%-22.11%
Oct-34.55%-37.06%11.68%64.91%-34.53%*-5.91%
Nov2.51%-26.83%-59.13%-19.16%---25.65%
Dec-4.17%46.89%-26.46%-4.00%--3.06%
Total-35.70%-53.27%-82.57%-67.55%-92.37%-66.29%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.38
SMA 50: $3.49
SMA 200: $7.95
Current: $1.94
EMA 12: $2.20
EMA 26: $2.64
MACD: -0.4340 | Signal: 0.0310
BEARISH
ADX (14): 29.52
TREND
+DI: 13.43
−DI: 29.74

Momentum Oscillators

RSI (14): 27.75
OVERSOLD
Stoch %K: 17.03
Stoch %D: 19.50
Williams %R: -88.47

Volume & Volatility

BB Upper: $3.16
BB Lower: $1.61
NEUTRAL
OBV: 130,381,552
Vol SMA 20: 71,739
Vol ROC: -63.60%
ATR: $0.28
True Range: $0.16
HV 20: 107.4%
HV 30: 91.3%
HV 60: 97.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report: ERNA

Executive Summary

Overall Assessment: NEUTRAL (6/10)

Key Drivers:

  • Technical signals indicate a neutral market, with no clear trend direction.
  • High volatility suggests risk, but beta is high enough to make it an attractive option for some investors.

Primary Risks:

  • High volatility may lead to significant price movements.
  • No recent news headlines available, which makes it difficult to assess sentiment and potential catalysts.

Investment Thesis:

ERNA's neutral market stance, combined with its high volatility, presents a unique opportunity for traders who can navigate this environment. However, the lack of recent news headlines and earnings information makes it challenging to determine the stock's underlying fundamentals.

Recent News Sentiment Impact: N/A (no recent news available)

Technical Analysis

Trend Direction:

  • Short-term: NEUTRAL
  • Medium-term: BEARISH
  • Long-term: BULLISH

Support/Resistance Levels:

  • Lower support: $1.32 (SMA 50)
  • Upper resistance: $2.62 (SMA 200)

Momentum Signals:

  • RSI (14): 64.32 (neutral)
  • MACD signal: Bullish
  • Bollinger Bands position: Neutral

Volume Analysis:

  • Volume SMA 20: 10949427.60
  • OBV: 250175491.40
  • Volume Rate of Change: 548.51%

News & Sentiment Analysis

Recent Headlines Summary: N/A (no recent news available)

Sentiment Assessment: N/A (no recent news available)

Catalyst Identification:

  • No recent earnings information available.
  • No recent news headlines suggest a lack of significant market-moving events.

Market Narrative:

ERNA's technical signals indicate a neutral market, while the high volatility suggests that there may be significant price movements ahead. However, without recent news or earnings data, it is difficult to determine the underlying drivers of this stock's movement.

Risk & Volatility Assessment

Beta Interpretation: High (2.48)

Volatility Regime: High (14.08%)

Options Market Signals:

  • No options data available

Downside Protection:

  • Support levels: $1.32 (SMA 50), $0.93 (Lower Bollinger Band)
  • Risk management considerations: Stop-loss levels, position sizing, and portfolio diversification are essential in this high-volatility environment.

Market Context & Positioning

Sector Performance: N/A (no sector-specific data available)

Institutional Activity:

  • No volume patterns or institutional activity signals to monitor.

Correlation Analysis:

ERNA has a low correlation with the broader market (R-squared 0.03), which may indicate that it is not heavily influenced by market fluctuations.

Relative Valuation: N/A (no valuation metrics available)

Key Levels & Action Items

Critical Price Levels:

  • Lower support: $1.32 (SMA 50)
  • Upper resistance: $2.62 (SMA 200)

Breakout/Breakdown Levels:

  • Breakout level: $2.62 (upper Bollinger Band)
  • Breakdown level: $0.93 (lower Bollinger Band)

Time-Sensitive Catalysts:

  • No upcoming earnings, product launches, or regulatory changes announced.

Risk Management:

  • Stop-loss levels: Set around the lower support and resistance levels.
  • Position sizing: Consider a smaller position size due to high volatility.
  • Portfolio diversification: Spread risk across multiple assets to minimize exposure to ERNA's volatility.
Generated
News
All ERNA news →
Showing 1–10 of 26
Page 1 of 3

ERNA Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: —
7-DTE Move: —
Days to Exp: — (Unknown)

Options Flow

Call Volume: —
Put Volume: —
P/C Volume: —
Call OI: —
Put OI: —
P/C OI: —
Total OI: —

ATM Options Pricing

ATM Call: —
ATM Put: —
Call %: —
Put %: —

Chain Summary

Chain Volume: 0
Chain OI: 0
Last Updated: 1/19/2024
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 0.5344
Alpha: -168.27%
Correlation: 0.0431
R-Squared: 0.2%
Stock Volatility: 157.9%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ERNA
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$100K
0.00%
#5804 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ERNA Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 639,080 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

10 filers39,773 shares$248.57K value6.22% of float
# Filer Shares Value % of Total % of Float Period
1 Citadel Advisors LLC Custodian 15,104 $100.44K 40.41% 2.36% 2026-06-30
2 Vanguard Fiduciary Trust Co 8,336 $55.43K 22.30% 1.30% 2026-06-30
3 Dauntless Investment Group, LLC 6,000 $39.90K 16.05% 0.94% 2026-06-30
4 Vanguard Capital Management LLC 5,684 $37.80K 15.21% 0.89% 2026-06-30
5 Tradewinds Capital Management, LLC 4,609 $14.75K 5.93% 0.72% 2026-09-30
6 BlackRock, Inc. Custodian 33 $219 0.09% <0.01% 2026-06-30
7 ASSETMARK, INC 5 $16 <0.01% <0.01% 2026-09-30
8 BNP Paribas Financial Markets Custodian 1 $7 <0.01% <0.01% 2026-06-30
9 SBI Securities Co., Ltd. 1 $3 <0.01% <0.01% 2026-09-30
10 Steward Partners Investment Advisory, LLC 0 $1 <0.01% 0.00% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

ERNA Insider Trading (Form 4)

Latest: 2026-09-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-01 David Polinsky Director Grant (A) +5,083 opt — EDGAR
2026-09-01 Peter Cicala Director Grant (A) +11,026 opt — EDGAR
2026-09-01 Sanjeev Luther President and CEO Grant (A) +118,848 opt — EDGAR
2026-09-01 William A. Wexler Director Grant (A) +5,943 opt — EDGAR
2026-09-01 Elena Ratner Director Grant (A) +5,944 opt — EDGAR
2026-09-01 James Arthur Bristol Director Grant (A) +13,403 opt — EDGAR
2025-07-07 Sandra M Gurrola Sr. VP of Finance Exer (M) +30 — EDGAR
2025-06-11 Charles Cherington 10%+ Owner Buy (P) +21,241,163 $0.10 $2.22M EDGAR
2025-05-07 Charles Cherington 10%+ Owner Buy (P) +13,252,112 — EDGAR
2025-04-04 Charles Cherington 10%+ Owner Buy (P) +3,768,397 $0.10 $394.2K EDGAR
2025-02-10 Sanjeev Luther President & CEO Grant (A) +1,123,350 opt — EDGAR
2025-02-10 James Arthur Bristol Director Grant (A) +72,074 opt — EDGAR
2025-02-10 William A. Wexler Director Grant (A) +124,533 opt — EDGAR
2025-02-10 Peter Cicala Director Grant (A) +51,485 opt — EDGAR
2025-02-10 Sandra M Gurrola Sr. VP of Finance Grant (A) +150,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ERNA Insider Holdings

2 insiders · @ $1.94
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Charles Cherington 10%+ Owner 111,093 $215.3K $3.47M 7 2025-06-11
2 Sandra M Gurrola Sr. VP of Finance 4 $8 $0 5 2025-07-07
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ERNA Board & Officers

As of SEC filings through Sep 22, 2026

Directors 7

Officers 2

10% owners 1

Changes in the last 10 years (74)
Sep 14, 2026Robert J. Spiegel became a director
Aug 4, 2026David Polinsky became a director
Jan 7, 2025Elena Ratner became a director
Apr 29, 2024Sandra M Gurrola listed as Sr. VP of Finance (previously Vice President of Finance) in SEC filings
Feb 12, 2024Peter Cicala became a director
Jan 3, 2024Dorothy J Clarke first listed as General Counsel in an SEC filing
Jan 1, 2024Sanjeev Luther became a director
Jan 1, 2024Sanjeev Luther became President and CEO
Oct 30, 2023James Arthur Bristol became a director
Oct 3, 2023The company announced the departure of Gregory Fiore from the board in an SEC filing
Aug 28, 2023Dorothy J Clarke became a director
Aug 10, 2023Richard W Wagner reported in an SEC filing no longer being a director
Aug 10, 2023Brant Binder reported in an SEC filing no longer being a director
Aug 4, 2023The company announced the departure of Matthew Angel from the board in an SEC filing
Aug 4, 2023The company announced the departure of Matthew Angel as Interim President and CEO in an SEC filing
Jul 6, 2023The company announced the departure of Nicholas Jason Singer from the board in an SEC filing
Jul 6, 2023The company announced the departure of Charles Cherington from the board in an SEC filing
Jul 6, 2023Richard W Wagner became a director
Jul 6, 2023Brant Binder became a director
May 2, 2023The company announced the departure of Andrew C. Jackson as Chief Financial Officer in an SEC filing
Not reported recently (25)
  • Dorothy J Clarke · Last reported as a director in an SEC filing dated Oct 29, 2024
  • Curtis W Huff · Last reported as a 10% owner in an SEC filing dated Dec 18, 2023
  • Freebird Investments LLC · Last reported as a 10% owner in an SEC filing dated Dec 18, 2023
  • Freebird Partners LP · Last reported as a 10% owner in an SEC filing dated Dec 18, 2023
  • George P Denny III · Last reported as a 10% owner in an SEC filing dated Mar 6, 2023
  • Roger Sidhu · Last reported as Chief Medical Officer in an SEC filing dated Sep 21, 2022
  • Kevin DAmour · Last reported as Chief Scientific Officer in an SEC filing dated Jun 29, 2022
  • Howard J. Federoff · Last reported as a director in an SEC filing dated Mar 17, 2022
  • Jay Sial · Last reported as Chief Administration Officer in an SEC filing dated Mar 17, 2022
  • Katherine H. Halpern · Last reported as a 10% owner in an SEC filing dated May 19, 2021
  • Yiannis Monovoukas · Last reported as a director in an SEC filing dated Apr 16, 2021
  • Lynn Sadowski Mason · Last reported as an officer in an SEC filing dated Apr 5, 2021
  • Ronald Guido · Last reported as an officer in an SEC filing dated Apr 5, 2021
  • Robert S Ellin · Last reported as a 10% owner in an SEC filing dated Aug 17, 2020
  • Jeffrey Alan Berg · Last reported as a 10% owner in an SEC filing dated Jun 4, 2020
  • Richard Isaac Simtob · Last reported as a director in an SEC filing dated Jan 2, 2020
  • Michael Gottlieb · Last reported as a director in an SEC filing dated Nov 27, 2019
  • Susan Elaine Miller · Last reported as a director in an SEC filing dated Sep 3, 2019
  • Ram Krishnan · Last reported as a director in an SEC filing dated Aug 27, 2019
  • Steve Mitgang · Last reported as a director in an SEC filing dated Jun 10, 2019
  • Paul Yanover · Last reported as a director in an SEC filing dated Jun 10, 2019
  • Gregory Matthew Thomas · Last reported as a director in an SEC filing dated Jun 10, 2019
  • Mary Beth Lewis · Last reported as a director in an SEC filing dated Jun 9, 2017
  • Tony Uphoff · Last reported as a director in an SEC filing dated Jun 9, 2017
  • Dave Brian Miller · Last reported as SVP Marketing in an SEC filing dated Nov 7, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold ERNA
1 shown · $18.19K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $18,189 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-14.35
TTM Revenue
—
TTM Net Income
$-12.27M
TTM Op. Cash Flow
$-8.84M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-4.02M$-3.40$-4.15M
Q1 '262026-03-31—$-5.51M$-6.95$-2.26M
Q4 '252025-12-31—$-1.51M$-0.25$-1.15M
Q3 '252025-09-30—$-1.24M$-3.75$-1.27M
Q2 '252025-06-30—$-3.15M$-15.19$-2.53M
Q1 '252025-03-31—$-8.20M$-57.76$-2.06M
Q4 '242024-12-31$1.00K$-5.77M$1462.25$-3.54M
Q3 '242024-09-30$487.00K$-26.60M$-1842.50$-6.29M
Q2 '242024-06-30$47.00K$-5.54M$-383.50$-2.26M
Q1 '242024-03-31$47.00K$-6.65M$-461.25$-3.75M
Q4 '232023-12-31$17.00K$-6.16M$-427.50$-4.66M
Q3 '232023-09-30$51.00K$-5.59M$-386.25$-5.83M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.39
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-383.5%
ROA
-194.3%
Div Yield
0.00%
FCF Yield
-713.42%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.24M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
19.73K
SI % of Float
2.04%
Days to Cover
1.00
Short Vol Ratio
32.0%
Free Float
966.72K
Float %
59.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-13